ContraVir Pharmaceuticals (NASDAQ:CTRV) Given a $4.00 Price Target by Maxim Group Analysts

Maxim Group set a $4.00 price objective on ContraVir Pharmaceuticals (NASDAQ:CTRV) in a report published on Monday, February 12th. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Separately, ValuEngine raised ContraVir Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, February 2nd.

Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at $0.26 on Monday. ContraVir Pharmaceuticals has a one year low of $0.23 and a one year high of $1.96.

An institutional investor recently bought a new position in ContraVir Pharmaceuticals stock. Anson Funds Management LP purchased a new position in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,237,957 shares of the biopharmaceutical company’s stock, valued at approximately $446,000. ContraVir Pharmaceuticals makes up approximately 0.3% of Anson Funds Management LP’s portfolio, making the stock its 26th largest position. Anson Funds Management LP owned 1.57% of ContraVir Pharmaceuticals as of its most recent SEC filing. 7.07% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “ContraVir Pharmaceuticals (NASDAQ:CTRV) Given a $4.00 Price Target by Maxim Group Analysts” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply